Per rectal diclofenac tablet (suppository) and inraveous fluid (Ringer lactate) are already proven for decreasing adverse effect (pancreatitis) after an endoscopic procedure (ERCP). We will be combining both methods to see whether they can further decrease the adverse effect of ERCP.
Not Applicable
- Conditions
- Health Condition 1: K87- Disorders of gallbladder, biliarytract and pancreas in diseases classified elsewhere
- Registration Number
- CTRI/2020/09/027536
- Lead Sponsor
- Department of Gastroenterology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients having high risk factors for post ERCP pancreatitis.
Exclusion Criteria
Pregnancy,
Patient with contraindication for diclofenac and ringer lactate,
Patient with active acute pancreatitis,
Patient not giving consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease in incidence of post ERCP pancreatitis in combination prophylaxis group,in comparison to prophylaxis by individual therapy(rectal diclofenac OR Ringers lactate)Timepoint: After 24 hours of procedure diagnosis of pancreatitis would be looked for.
- Secondary Outcome Measures
Name Time Method Decrease in hospital stayTimepoint: 24 hours after ERCP